Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEland Oil & Gas Regulatory News (ELA)

  • There is currently no data for ELA

Opuama Operations Update

16 Aug 2018 07:00

RNS Number : 9541X
Eland Oil & Gas PLC
16 August 2018
 

16 August 2018

Eland Oil & Gas PLC

("Eland" or the "Company")

 

Opuama Operations Update

 

 

Eland Oil & Gas PLC (AIM: ELA), an oil & gas production and development company operating in West Africa with an initial focus on Nigeria, is pleased to announce that its joint-venture subsidiary Elcrest Exploration and Production Nigeria Ltd ("Elcrest"), has successfully completed the Opuama-10 well and will be handing over to the Opuama field production team imminently.

 

Under the regulatory guidelines the Opuama production team will conduct a Maximum Efficient Rate Test ("MER Test"), testing the well at increasing choke sizes, following which the Company will update the market further when full testing is complete, and production is stabilised. Initial production from Opuama-10 is expected to be in line with previous guidance, at between 4,000 and 6,000 barrels of oil per day ("bopd") (1,800 to 2,700 bopd net to Elcrest), with total production from Opuama field expected to be in the range of 28,000 to 30,000 bopd (12,600 to 13,500 bopd net to Elcrest).

 

As previously announced by the Company on 25 July 2018, Opuama-10 encountered six oil-bearing reservoirs with 307 feet apparent vertical thickness, with the Opuama-10 well completed on two of these reservoirs, namely D1000 and D5000. Following a review by the OML 40 Joint Venture between Elcrest and the Nigerian Petroleum Development Company Ltd ("NPDC"), a decision has been made to accelerate the drilling of the Opuama-11 well with the target of developing incremental reserves from the intermediate zones not targeted by Opuama-10.

 

Following handover of Opuama-10 to the production team, the JV will move the OES Teamwork rig to Opuama-11, where it is intended to develop the D3500, D4000 and D2000 reservoirs. The Opuama-10 well recorded net pay in these three reservoirs of 168 feet apparent vertical thickness. It is expected that initial gross production from Opuama-11 will be between 4,000 and 6,000 bopd (1,800 to 2,700 bopd net to Elcrest).

 

Following Opuama-11 and completion of regulatory approvals, the rig will be moved to the Gbetiokun field, where it will re-enter well Gbetiokun-1 and drill well Gbetiokun-3 as part of the initial phase of the field development plan. Dredging operations have already commenced and are currently 50% complete. Dredging will be completed in time for rig mobilisation to Gbetiokun.

 

George Maxwell, CEO of Eland, commented:

"We are delighted that the recent successful infill drilling on Opuama field has led to the confirmation of a further near-term production well. The successful delivery of Opuama-11 will not only advance us past our previous production target of 30,000 barrels of oil per day but will also maximise near-term cashflows.

The upside on OML 40 remains significant and together with Elcrest's partner NPDC we look forward to continuing the previously-announced work programme on the licence, including the Early Production System and Full Field Development of Gbetiokun field and exploration drilling of Amobe Prospect.

I look forward to positively updating the market on operations in due course."

 

For further information:

 

Eland Oil & Gas PLC (+44 (0)1224 737300)

www.elandoilandgas.com

George Maxwell, CEO

Ronald Bain, CFO

Finlay Thomson, IR

 

Canaccord Genuity Limited (+44 (0)20 7523 8000)

Henry Fitzgerald O'Connor / James Asensio

 

Panmure Gordon (UK) Limited (+44 (0)20 7886 2500)

Adam James / Atholl Tweedie

James Stearns

 

Camarco (+44 (0) 203 757 4980)

Billy Clegg / Georgia Edmonds / Tom Huddart

 

 In accordance with the guidelines of the AIM Market of the London Stock Exchange, Yannis Korakakis, MSc of Leoben University, with 32 years of experience in the oil and gas sector, is a Petroleum Engineer and member of the Society of Petroleum Engineers who meets the criteria of qualified persons under the AIM guidance note for mining and oil and gas companies, has reviewed and approved the technical information contained in this announcement.

 

Notes to editors:

Eland Oil & Gas is an AIM-listed independent oil and gas company focused on production and development in West Africa, particularly the highly prolific Niger Delta region of Nigeria.

Through its joint venture company Elcrest, Eland's core asset is a 45% interest in OML 40 which is in the Northwest Niger Delta approximately 75km northwest of Warri and has an area of 498km². 

In addition, the Company has a 40% interest in the Ubima Field, onshore Niger Delta, in the northern part of Rivers State.

The OML 40 licence holds gross 2P reserves of 83.4 mmbbls, gross 2C contingent resources of 40.4 mmbbls and a best estimate of 254.5 mmbbls of gross un-risked prospective resources*

The Ubima field holds gross 2P reserves of 2.4 mmbbls of oil and gross 2C resource estimates of 31.1 mmbbl**

Net production figures relate to Elcrest Exploration and Production Nigeria Ltd ("Elcrest"), Eland's joint venture company. Production rates, when oil is exported via Forcados, are as measured at the Opuama PD meter, are subject to reconciliation and will differ from sales volumes.

*Netherland, Sewell & Associates Inc CPR report 31 December 2017

**AGR TRACS April 2016

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
UPDSFLEFIFASEIA
Date   Source Headline
15th Nov 20062:50 pmRNSAnnual Report
25th Oct 20062:18 pmRNSBlocklisting Interim Review
25th Oct 20067:30 amBUSElan Reports Third Quarter 2006 Financial Results
24th Oct 20061:00 pmBUSTYSABRI(R) Maintained Remission in Patients with Moderate-to-Severe Crohn's Disease Treated for Longer Than Two Years According to Data Presented This Week
18th Oct 20068:42 amRNSHolding in Company
10th Oct 20067:00 amBUSNotice of Results
6th Oct 20062:07 pmBUSNew Pharmacoeconomic Data on TYSABRI(R) Demonstrate Significant Reduction in Steroid Use and Hospitalizations in Patients with Multiple Sclerosis
4th Oct 20061:00 pmBUSHealth Canada Grants Approval of TYSABRI(TM) (natalizumab) for the Treatment of Multiple Sclerosis Following Priority Review
29th Sep 20062:00 pmBUSNew Data Presented at ECTRIMS Congress Show TYSABRI(R) Has Sustained Effect on Relapse Rate in Multiple Sclerosis Patients Treated for up to Three Years
11th Sep 200611:57 amRNSFinancial Statements
9th Aug 20068:58 amRNSHolding in Company
2nd Aug 20065:26 pmRNSDirector/PDMR Shareholding
2nd Aug 200612:12 pmRNSHolding in Company
29th Jun 200612:32 pmRNSHolding in Company
21st Jun 200610:01 amRNSHolding in Company
15th Jun 20068:20 amRNSHolding in Company
7th Jun 20068:02 amRNSFurther re Appointment
1st Jun 200611:58 amRNSHolding in Company
25th May 20063:31 pmRNSHolding in Companies
25th May 200612:37 pmRNSHolding in Company
19th May 20065:51 pmRNSDirectors/PDMR Shareholding
19th May 200610:56 amRNSHolding in Company
17th May 200612:16 pmRNSHolding in Company
12th May 20061:45 pmRNSDirector/PDMR Shareholding
24th Apr 200611:36 amRNSHolding in Company
20th Apr 20064:44 pmRNSDocument Availability
19th Apr 20063:30 pmRNSHolding in Company
13th Apr 200612:51 pmRNSHolding in Company
13th Apr 200612:04 pmRNSAnnual Information Update
10th Apr 200612:42 pmRNSBrochure of Particulars
3rd Apr 20063:39 pmRNSBrochure of Particulars
13th Mar 200611:47 amRNSHoldings in Company
10th Mar 20063:24 pmRNSDirector/PDMR Shareholding
9th Mar 20067:30 amRNSRestoration of Listing
9th Mar 20067:01 amRNSOL Notice - Restoration
7th Mar 20061:00 pmRNSSuspension - Elan Corp Plc
7th Mar 20061:00 pmRNSOL Notice - Suspension
15th Feb 200610:15 amRNSBrochure of Particulars
10th Feb 20064:55 pmRNSDirector/PDMR Shareholding
9th Feb 20065:32 pmRNSDirector/PDMR Shareholding
9th Feb 20063:54 pmRNSHolding in Company
8th Feb 200610:56 amRNSDirector/PDMR Shareholding
3rd Feb 20069:58 amRNSDirector/PDMR Shareholding
25th Jan 200611:19 amRNSHolding in Company
9th Dec 20054:02 pmRNSDirector/PDMR Shareholding
17th Nov 20052:31 pmRNSRE:Director/PDMR Shareholding
1st Nov 20055:32 pmRNSDirector/PDMR Shareholding
22nd Sep 20059:43 amRNSRe: Brochure of Particulars
23rd Aug 20055:12 pmRNSDirector/PDMR Shareholding
21st Jun 200511:32 amRNSBrochure of Particulars

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.